Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Search trials by disease or condition

Enter a condition, keyword, or NCT ID

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “breast cancer”

Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI TrialRecruiting
NCT07191717Phase 2Updated Aug 20, 2026
Sponsor: Jonsson Comprehensive Cancer Center
Anatomic Stage I Breast Cancer AJCC v8 · Anatomic Stage II Breast Cancer AJCC v8 · Anatomic Stage III Breast Cancer AJCC v8 · Invasive Breast Carcinoma
United States
A Study of Romosozumab in People With Breast Cancer and OsteoporosisRecruiting
NCT07776613Phase 2Updated Aug 20, 2026
Sponsor: Memorial Sloan Kettering Cancer Center
Breast Cancer · Metastatic Breast Cancer (MBC)
United States
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of TreatmentActive Not Recruiting
NCT06105632Phase 2Updated Aug 20, 2026
Sponsor: Pfizer
Advanced or Metastatic Breast Cancer
United States, Argentina, Australia, Brazil, Canada +9 more
Physical Activity and Healthy Aging: Promoting Cardio-metabolic Capacity to Fight Chronic Inflammation and Improve Outcomes in Breast Cancer Patients (PhActHealth Study)Recruiting
NCT07776951NAUpdated Aug 20, 2026
Sponsor: University of Milan
Breast Cancer
Italy
HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term RemissionRecruiting
NCT07459673Phase 2Updated Aug 20, 2026
Sponsor: Memorial Sloan Kettering Cancer Center
Breast Cancer · HER2-positive Breast Cancer · Breast Cancer Stage IV
United States
Application of CT-Linac-Based "All-in-One" One-Stop Radiotherapy in Breast CancerRecruiting
NCT07776301NAUpdated Aug 20, 2026
Sponsor: Fudan University
Breast Cancer
China
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid TumorsActive Not Recruiting
NCT04557449Phase 2Updated Aug 20, 2026
Sponsor: Pfizer
Liposarcoma · Prostate Cancer · Breast Neoplasms · Adenocarcinoma of Lung
United States, Argentina, China, Czechia, Japan +3 more
A Study to Understand the Patients Confirmed to Have Advanced or Metastatic Breast Cancer and Receiving Palbociclib Treatment Using a Real-world DatabaseCompleted
NCT06962969N/AUpdated Aug 20, 2026
Sponsor: Pfizer
Advanced or Metastatic Breast Cancer
United States
A TEACH-BACK APPROACH TO INCREASE BREAST CANCER KNOWLEDGE IN WOMEN WITH LOW HEALTH LITERACY: AN INTERVENTION STUDYNot Yet Recruiting
NCT07777289NAUpdated Aug 20, 2026
Sponsor: Buca Seyfi Demirsoy State Hospital
Health Literacy · Breast Cancer Awareness
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid TumorsRecruiting
NCT05269381Phase 1, Phase 2Updated Aug 20, 2026
Sponsor: Mayo Clinic
Anatomic Stage III Breast Cancer AJCC v8 · Anatomic Stage IIIA Breast Cancer AJCC v8 · Anatomic Stage IIIB Breast Cancer AJCC v8 · Anatomic Stage IIIC Breast Cancer AJCC v8
United States
Audit of Targeted Sentinel Node Biopsy (TSNB) in Patients With Limited Nodal Disease Undergoing Primary SurgeryRecruiting
NCT07085442N/AUpdated Aug 20, 2026
Sponsor: University Hospitals of Derby and Burton NHS Foundation Trust
Breast Cancer · Axillary Lymph Nodes Dissection · Axillary Metastases · Sentinel Lymph Node Biopsy (SLNB)
United Kingdom
A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.Active Not Recruiting
NCT06247995Phase 1, Phase 2Updated Aug 20, 2026
Sponsor: Novartis Pharmaceuticals
Breast Cancer
United States, Australia, Canada, China, France +6 more
Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast CancerActive Not Recruiting
NCT06027268Phase 2Updated Aug 20, 2026
Sponsor: Wake Forest University Health Sciences
Metastatic Triple-Negative Breast Cancer
United States
Low Dose Aspirin for the Prevention of Postpartum Related Breast CancerRecruiting
NCT05557877Phase 2Updated Aug 20, 2026
Sponsor: Mayo Clinic
Breast Carcinoma
United States
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast CancerRecruiting
NCT06058377Phase 3Updated Aug 20, 2026
Sponsor: National Cancer Institute (NCI)
Anatomic Stage II Breast Cancer AJCC v8 · Anatomic Stage III Breast Cancer AJCC v8 · HER2-Negative Breast Carcinoma · Hormone Receptor-Positive Breast Carcinoma
United States, Puerto Rico
LiveWell mBc: Adapted Dialectical Behavioral Therapy Skills TrainingNot Yet Recruiting
NCT07539649NAUpdated Aug 20, 2026
Sponsor: Medical University of South Carolina
Survivorship
Monitoring for CardioToxicity Using WeArable deVices While Undergoing cancEr Treatments (MCT-WAVE)Not Yet Recruiting
NCT07776964NAUpdated Aug 20, 2026
Sponsor: University of Minnesota
Cardiotoxicity · Cancer · Cardiac Arrhythmia · Left Ventricular Dysfunction
United States
Dosing Physical Activity Among Older Cancer Survivors Who Experience Chronic Pain: a Micro-randomized TrialRecruiting
NCT07227077NAUpdated Aug 20, 2026
Sponsor: Medical College of Wisconsin
Breast Cancer · Cervical Cancer · Bladder Cancer · Colorectal Cancer
United States
A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast CancerActive Not Recruiting
NCT05394259Phase 1Updated Aug 20, 2026
Sponsor: M.D. Anderson Cancer Center
Pancreatic Cancer · Breast Cancer · Hepatocellular Carcinoma
United States
MRI-Based Preoperative Accelerated Partial Breast IrradiationActive Not Recruiting
NCT02728076NAUpdated Aug 20, 2026
Sponsor: Medical College of Wisconsin
Breast Cancer
United States
DESTINY Breast Respond HER2-(Ultra)Low EuropeRecruiting
NCT05945732N/AUpdated Aug 19, 2026
Sponsor: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Unresectable Breast Cancer · Metastatic Breast Cancer · HER2-low Expressing Breast Cancer · HER2-(Ultra)Low Expressing Breast Cancer
Austria, Belgium, Denmark, France, Italy +5 more
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic CancerRecruiting
NCT01174121Phase 2Updated Aug 19, 2026
Sponsor: National Cancer Institute (NCI)
Metastatic Colorectal Cancer · Metastatic Pancreatic Cancer · Metastatic Ovarian Cancer · Metastatic Breast Carcinoma
United States
Multiparametric MRI as a Non-Invasive Biomarker of the Tumor MicroenviromentSuspended
NCT04803084N/AUpdated Aug 19, 2026
Sponsor: Laura Kennedy
Breast Cancer · Triple-negative Breast Cancer
United States
BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic DiseaseRecruiting
NCT07492641Phase 3Updated Aug 19, 2026
Sponsor: BeOne Medicines
HR+/HER2- Breast Cancer
United States, Australia, Brazil, China, Japan +5 more
Trial of Retifanlimab With Trastuzumab and Pertuzumab Combination in HER2-Addicted Breast CancerNot Yet Recruiting
NCT07772245Phase 2Updated Aug 19, 2026
Sponsor: Polly A. Niravath, MD
HER2-addicted Breast Cancer

Previous page Next page